Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia/Ib clinical trial
Our Phase Ia findings demonstrate the well-tolerability of PT-CY/BEN and its association with early engraftment, a more diverse T-cell repertoire, and earlier CD4+ T-cell reconstitution. Future studies are warranted to confirm our findings and investigate potential additional benefits of PT-CY/BEN over PT-CY alone.
Authors
- Forrest L. Baker (ORCID: https://orcid.org/0000-0001-5338-7905)
- Jessica Stokes (ORCID: https://orcid.org/0000-0003-1075-3324)
- Emmanuel Katsanis (ORCID: https://orcid.org/0000-0003-1466-6965)
- Richard J. Simpson (ORCID: https://orcid.org/0000-0002-7064-6881)
- Dan Davini
- Megan J. Cracchiolo
Institutions
- University of Arizona (US)
- Banner - University Medical Center Tucson (US)
- University of Arizona Cancer Center
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1568862
- Citations
- 1
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Leukemia and Lymphoma Society
- University of Arizona Cancer Center